Klivira
Request demo

Navigating Aetna Ketamine Infusion Prior Authorization

Efficiently managing **Aetna Ketamine Infusion prior authorization** is critical for revenue cycle integrity and patient access. Klivira provides the automation and intelligence needed to navigate Aetna's specific requirements.

Ketamine infusion therapy, often billed under CPT codes like 96360-96361, is a procedure frequently subject to stringent medical necessity review across commercial, Medicare Advantage, and Medicaid managed care plans. For providers serving Aetna members, understanding the payer's specific submission protocols and clinical criteria is paramount to minimizing authorization delays and denials.

Aetna's Prior Authorization Channels for Medical Benefits

Aetna primarily processes medical benefit precertification requests, including those for Ketamine Infusion therapy, through the Availity provider portal. For organizations with established electronic data interchange (EDI) capabilities, Aetna also supports X12 278 transactions via clearinghouses for eligible procedure categories, offering an automated submission pathway.

Understanding Aetna's Medical Necessity Criteria for Ketamine Infusion

Aetna publishes its medical necessity criteria in Clinical Policy Bulletins (CPBs), which are publicly accessible and versioned. For Ketamine Infusion, providers must consult the relevant CPB to understand specific clinical indications, site-of-service requirements, and documentation standards, which may include prior conservative treatment requirements or specific diagnostic imaging.

Common Aetna Denial Reasons for Infusion Therapy

  • Lack of documented medical necessity or insufficient clinical support.
  • Failure to meet step therapy or prior conservative treatment requirements.
  • Inappropriate site of service (e.g., outpatient vs. inpatient).
  • Off-label use without adequate compendium or policy support.
  • Benefit exclusion or non-covered service.

Aetna Prior Authorization Turnaround Times

Prior authorization turnaround times for Aetna plans are influenced by state-specific regulations and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid managed care lines (Aetna Better Health), CMS-0057-F mandates 72-hour standard and 24-hour expedited decisions, with phased compliance through 2027. Commercial plans follow different state and accreditation-driven timelines.

Electronic Prior Authorization Initiatives and Aetna

Aetna utilizes ePA partners like CoverMyMeds and Surescripts for pharmacy benefit submissions, administered through CVS Caremark. For medical benefit procedures like Ketamine Infusion, the landscape for fully electronic prior authorization is evolving. While Aetna supports X12 278, direct Da Vinci PAS IG conformance for medical benefit PA requires verification against current public disclosures, as the industry transitions towards API-driven workflows.

Peer-to-Peer Review and Appeals for Ketamine Infusion Denials

In the event of an Aetna denial for Ketamine Infusion, providers typically have access to a structured appeal pathway, starting with reconsideration or a peer-to-peer review with an Aetna medical director. This allows for direct clinical discussion regarding medical necessity. Formal appeals and external review options are also available, with timely filing windows varying by line of business and state regulations.

Frequently asked questions

Which CPT codes are typically used for Ketamine Infusion therapy and require Aetna prior authorization?

Ketamine Infusion therapy is commonly billed using CPT codes such as 96360 (initial) and 96361 (subsequent) for therapeutic infusions. Aetna generally requires prior authorization for these procedures, particularly when administered in an outpatient setting, to evaluate medical necessity against their Clinical Policy Bulletins.

How can I submit a prior authorization request for Ketamine Infusion to Aetna?

For medical benefit services, Aetna primarily accepts prior authorization requests through the Availity provider portal. Practices with integrated systems can also submit X12 278 transactions via their clearinghouse. It's crucial to include comprehensive clinical documentation to support medical necessity.

Where can I find Aetna's specific medical policy criteria for Ketamine Infusion?

Aetna's medical necessity criteria, including those for Ketamine Infusion, are published in their public Clinical Policy Bulletins (CPBs). These documents outline the specific clinical indications, contraindications, and documentation requirements necessary for approval. Always refer to the most current version of the relevant CPB.

What are common reasons Aetna denies Ketamine Infusion prior authorization requests?

Common denial reasons include insufficient documentation of medical necessity, failure to meet step therapy or prior conservative treatment requirements, inappropriate site of service, or off-label use without supporting evidence. Understanding the applicable CPB can help mitigate these issues.

Does Klivira integrate with Aetna's prior authorization systems for Ketamine Infusion?

Klivira automates the prior authorization workflow by integrating with EMRs and connecting to payer portals like Availity, and by facilitating X12 278 transactions. This streamlines the submission process for procedures like Ketamine Infusion, helping ensure all required documentation is included for Aetna's review.

Related coverage

Other ketamine-infusion prior authorization by payer

Other ketamine-infusion prior authorization by specialty

Ready to automate prior auth for this procedure?

See how Klivira automates prior authorizations for your team.

Request a demo